European Journal of Clinical Pharmacology

, Volume 26, Issue 5, pp 651–653 | Cite as

Intra-individual consistency of prednisolone kinetics during long-term prednisone treatment

  • E. Langhoff
  • H. Flachs
  • J. Ladefoged
  • E. F. Hvidberg
Short Communications


Eleven patients on long-term prednisone treatment were studied on two occasions separated by 45 to 325 days. In 10 patients the total body clearance of prednisolone only changed about 10%. In one case a 78.5% decrease was observed after stopping treatment with rifampicin and isoniazide. No association was found between the prednisone dose rate (mg/kg per month), patient age or mean endogenous plasma hydrocortisone level and prednisolone clearance/kg. The results indicate considerable intra-individual consistency of prednisolone kinetics if other conditions are not changed.

Key words

prednisolone prednisone treatment pharmacokinetics individual variation microsomal enzyme induction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderson RG, Wheatley T, English J, Chakraborty J, Marks V (1979) Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone. Br J Med 1: 1534–1536Google Scholar
  2. 2.
    Gambertoglio JG, Amend WJC Jr, Benet LZ (1980) Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokin et Biopharm 8: 1–52Google Scholar
  3. 3.
    Frey FJ, Lozada F, Guentert T, Frey BM (1981) A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone. Eur J Clin Pharmacol 19: 209–212Google Scholar
  4. 4.
    Matsuzawa T, Sugimoto N, Ishiguro I (1981) A simple micromethod for determining human serum cortisol by high-pressure liquid chromatography using 0.1 ml serum. Anal Biochem 115: 250–253Google Scholar
  5. 5.
    Gambertoglio JG, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O Jr, Amend WJC Jr (1980) Prednisolone disposition in cushingoid and non-cushingoid kidney transplant patients. J Clin Endocrinol Metab 51: 561–565Google Scholar
  6. 6.
    Frey FJ, Amend WJC, Lozada F, Frey BM, Holford NHG, Benet LZ (1982) Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients. Eur J Clin Pharmacol 21: 235–242Google Scholar
  7. 7.
    Gambertoglio JG, Felix JF, Holford NHG, Birnham JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O Jr, Amend MJC Jr (1982) Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int 21: 621–626Google Scholar
  8. 8.
    Rose JQ, Yurchak AM, Jusko WJ (1978) Bioavailability of two 50 mg prednisone formulations in man. (Abstract) APhA Acad Pharm Sci 8: 138Google Scholar
  9. 9.
    Meikle AW, Weed JA, Tyler FH (1975) Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunoassays. J Clin Endocrinol Metab 41: 717–721Google Scholar
  10. 10.
    Bergrem H, Grøttum P, Rugstad HE (1983) Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Eur J Clin Pharmacol 24: 415–419Google Scholar
  11. 11.
    Uribe M, Schalm SW, Summerskill WHJ, Go VLW (1978) Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut 19: 1131–1135Google Scholar
  12. 12.
    Davis M, Williams R, Chakraborty J, English J, Marks V, Ideo G, Tempini S (1978) Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Br J Clin Pharmacol 5: 501–505Google Scholar
  13. 13.
    Frey FJ, Amend WJC Jr, Lozada F, Frey BM, Benete LZ (1981) Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. J Clin Endocrinol Metab 53: 1076–1080Google Scholar
  14. 14.
    Araki Y, Yokota O, Tatsuo K, Kashima M, Miyazaki T (1965) Steroid dynamics. Academic Press, New York, p 463Google Scholar
  15. 15.
    Kozower M, Veatch L, Kaplan M (1974) Decreased clearance of prednisolone, a factor in the development of corticosteroid side-effects. J Clin Endocrinol Metab 38: 407–412Google Scholar
  16. 16.
    Öst L, Björkhem I, Bahr C von (1984) Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. Eur J Clin Pharmacol 26: 363–369Google Scholar
  17. 17.
    McAllister WAC, Thompson PJ, Al-Habet SM, Rogers HJ (1983) Rifampicin reduces effectiveness and bioavailability of prednisone. Br Med J 286: 923–925Google Scholar
  18. 18.
    Wassner SJ, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Fine RN (1977) Allograft survial in patients receiving anticonvulsant medications. Clin Nephrol 8: 293–297Google Scholar
  19. 19.
    Buffington GA, Dominguez JH, Piering WF, Hebert LA, Kauffman HM, Lemann J (1976) Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. Am Med Assoc 236: 1958–1960Google Scholar
  20. 20.
    Bergrem H, Hervell J, Flatmark A (1983) Different prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Clin Pharmacol Ther 33: 249Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • E. Langhoff
    • 1
  • H. Flachs
    • 2
  • J. Ladefoged
    • 3
  • E. F. Hvidberg
    • 4
  1. 1.Tissue Typing Laboratory of the Department of Clinical ImmunologyUniversity HospitalCopenhagenDenmark
  2. 2.Department of Clinical Chemistry, CLUniversity HospitalCopenhagenDenmark
  3. 3.Medical Department P, Division of NephrologyUniversity HospitalCopenhagenDenmark
  4. 4.Department of Clinical PharmacologyUniversity HospitalCopenhagenDenmark

Personalised recommendations